Loading…

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, A Novel Poly (ADP-Ribose) Polymerase-1 Inhibitor in First-In-Human Study of Healthy Volunteers

Background JPI-289 is a promising poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. The plasma and urine concentrations of JPI-289 and its metabolites were determined using a v...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2017-08, Vol.39 (8), p.e48-e48
Main Authors: Han, S, Kim, Y.H, Choi, H. Youn, Soh, D.-J, Kim, J.-M, Nam, J.-W, Kim, J.-W, Bae, K.-S, Lim, H.-S
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background JPI-289 is a promising poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. The plasma and urine concentrations of JPI-289 and its metabolites were determined using a validated liquid chromatography-mass spectrometry method.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2017.05.148